Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity
Citations Over TimeTop 10% of 2009 papers
Abstract
Multinuclear platinum anticancer complexes are a proven option to overcome resistance of established anticancer compounds. Transferring this concept to ruthenium complexes led to the synthesis of dinuclear Ru(II)-arene compounds containing a bis(pyridinone)alkane ligand linker. A pronounced influence of the spacer length on the in vitro anticancer activity was found, which is correlated to the lipophilicity of the complexes. IC(50) values in the same dimension as for established platinum drugs were found in human tumor cell lines. No cross-resistance to oxoplatin, a cisplatin prodrug, was observed for the most active complex in three resistant cell lines; in fact, a 10-fold reversal of sensitivity in two of the oxoplatin-resistant lines was found. (Bio)analytical characterization of the representative examples showed that the ruthenium complexes hydrolyze rapidly, forming predominantly diaqua species that exhibit affinity toward transferrin and DNA, indicating that both proteins and nucleobases are potential targets.
Related Papers
- → Transferring the Concept of Multinuclearity to Ruthenium Complexes for Improvement of Anticancer Activity(2009)184 cited
- → Cellular trafficking, accumulation and DNA platination of a series of cisplatin-based dicarboxylato Pt(IV) prodrugs(2015)56 cited
- → Influence of the Linker Length on the Cytotoxicity of Homobinuclear Ruthenium(II) and Gold(I) Complexes(2017)36 cited
- → Design and investigation of photoactivatable platinum(iv) prodrug complexes of cisplatin(2019)24 cited
- A Novel Approach to Prostate Cancer Chemotherapy: Design of Prodrugs for Tissue-Specific Activation(2001)